Back flow thrombectomy and PIHP for the treatment of multiple bilobular HCC with Vp4 PVTT Alteration of energy metabolism and subsequent oxidative stress in the pathogenesis of cholangiopathy in primary biliary cirrhosis
Jinjun Wang,Madhu S. Budamagunta,J. Voss,M. Kurth,Kit S. Lam,Ling Lu,T. Kenny,C. Bowlus,Kenta Kikuchi,R. Coppel,A. Ansari,P. Leung,Jun Zhang,Weici Zhang,Guo‐Xiang-X. Yang,Sandeep Dhaliwal,Christopher,L. Bowlus,M. Gershwin
2013-01-01
Abstract:(Background) We have previously reported the efficacy of dual treatment, which is consisted of reductive hepatectomy and per-cutaneous isolated hepatic perfusion (PIHP), for patients with advanced HCC. However these patients are frequently compli-cated with Vp4 portal vein tumor thrombus (PVTT), and con-ventional en bloc resection is not always feasible. To overcome this situation, we have developed back flow thrombectomy (BFT) technique. For right hemihepatectomy with Vp4 PVTT, which reached to the contralateral left second portal branch, the portal trunk should be at first clamped at the superior bor-der of the pancreas. After one transverse venotomy at an appropriate site of the right portal branch, tumor thrombus is extracted by forceps and scissors using suction devices. Of particular note, the vascular clamp at the left first portal branch should be avoided because it may split PVTT and enhance portal vein embolization with fragmented tumor thrombus. Instead, back flow pressure in the portal system generated by BFT technique should be kept throughout the thrombectomy procedure. This pressure eases effective extraction of both micro- and macroscopic cancer nests liberated to the blood stream and avoid the migration into the future remnant liver. (Methods) Until the end of 2011, 43 multiple bilobular HCC patients with Vp4 were performed reductive hepatectomy with tumor thrombectomy. In 22 of 43 patients, BFT techniques were used. Sixteen of 23 patients had PVTT in the contralateral second portal branch. Seventeen of 43 patients were not performed PIHP because of economical reason, extrahepatic metastases, aggressive tumor progression, hepatic dysfunction, infectious complications or unfavorable conditions after surgery. (Results) Patency of portal vein at thrombectomy site of all/BFT patients 3 and 6 months after hepatectomy were 92%/90% and 87%/86%, respectively. The median OS of all 43 patients was 14 months and the 1 and 3-year OS rate was 55.5% and 19.1% respectively. In 26 patients who could undergo PIHP as second treatment, the median OS was 17 months and the 1 and 3-year OS rate was 69.2% and 23.1% respectively. (Con-clusions) Tumor thrombectomy by BFT technique allows multi-disciplinary treatment for patients with PVTT. An impressively increased survival rate achieved by additional PIHP supports the dual treatment strategy for multiple bilobular HCC patients with Vp4 PVTT. Background & Aims: Alkaline phosphatase (AP) is an important serum marker in primary sclerosing cholangitis (PSC). Patients with biliary obstructions of the large bile ducts due to dominant strictures resemble a special, clinically important phenotype. We aimed to assess the value of AP in predicting outcome depending on the presence of dominant strictures. Patients and methods: This is a prospective cohort study of 200 PSC patients that were treated with UDCA and endoscopic interventions over the period 1987–2011 in our tertiary care center. Laboratory values were examined in at least yearly intervals. Results: The median AP level at inclusion into the study was 299.0 ± 22.1 IU/l. Patients with dominant stenosis (DS) showed higher AP levels at first presentation (416.6 IU/l vs. 316.7 IU/l). 105 patients (52.5%) reached a sustained AP reduction below 1.5 x ULN between six and twelve month after inclusion into the study. The proportion of successful AP reduction did not differ between patients with or without DS (53.1% vs. 51.7%). We performed further subgroup analysis for patients without DS (group A, n=86), DS at first presentation (group B, n=50) and development of DS during the course of the study (group C, n=64). Reduction of AP below 1.5 x ULN within six to twelve month was associated with better outcome in group A (log rank: p=0.045) and group C (log rank: p=0.005) and showed a strong trend for group B (log rank: p=0.08). Evaluation of reduction of bilirubin and gamma-glutamyltransferase levels showed no impact on survival. Failed reduction of none of the three serum Purpose: Primary biliary cirrhosis (PBC) is considered a Th1-dominant autoimmune response and Th1 effector cells are critical for the development of cholangitis. However, more recent data provides evidence that the Th17 effector cell response are also involved in disease pathogenesis. Our laboratory has described a unique model of murine autoimmune cholangitis in which disease is induced following immunization with 2-octynoic acid coupled to BSA (2OA-BSA), a compound identified following extensive quantitative structure activity relationships of AMAs on human PBC sera. The identification of potential therapeutic targets would have major significance to translational therapy of humans with PBC. Methods: We have constructed several unique gene-deleted mice on the C57BL/6 background, including mice deleted of IL-12 p40, IL-12p35, IFN- γ , IL-23p19, IL-17A, IL-17F and IL-22 mice, immunized these animals with 2OA-BSA and followed the natural history of immunopathology to identify key pathways that might provide clues for successful therapy. Results: Our data indicate that whereas both IL-12/Th1 and IL-23/Th17 are involved in cholangitis, it is the IL-12/Th1 signaling pathway that elicits pathology. In fact, the induction of disease requires an IFN- γ response; deletion of IFN- γ prevents disease and suppresses autoantibodies. Importantly, deletion of the Th17 cytokine IL17A and IL-22, but not IL-17F, reduces biliary damage. In addition, IL-17A-knockout mice have reduced levels of anti-mitochondrial antibody (AMA). We further demonstrate that the production of IFN- γ was significantly decreased in the liver of IL-23p19-/-, IL-17A-/- and IL-22-/- mice as compared with control wild type mice. However, the ability of T cells to produce IFN- γ was not affected in these Th17 cytokine-deficient Conclusions: These data indicate that a deficient Th17 pathway may suppress the accumulation of IFN- γ producing cells in liver during the induction of cholangitis. The data also supports the thesis that whereas IFN- γ has a pivotal role in the inductive events involved in the pathogenesis of autoimmune cholangitis induced by 2OA-BSA, the IL-23/Th17 pathway potentiates IL-12/IFN- γ -mediated autoimmunity. These findings further refine our understanding of the pathways that need to be targeted for therapy of human PBC. We were recently able to demonstrate that CA19-9 values in patients with primary sclerosing cholangitis (PSC) depend on genotype of fucosyltransferase 2 and 3 (FUT2/3) and that patients with a high biosynthesis genotype are more likely to show increased CA19-9 values (Wannhoff et al. AASLD 2012). In this study we aimed to further investigate high CA19-9 values in PSC patients without malignancy. Therefore 210 tumor-free patients with well-defined PSC before liver transplantation were included. For 204 of these maximum CA19-9 with correspon-ding laboratory values were available. These included markers of cholestasis like alkaline phosphatase (ALP), total bilirubin and gamma glutamyl transferase (GGT) as well as markers of inflammation like leukocyte count and C-reactive protein (CRP). Median CA19-9 serum levels were 23.6 U/ml (interquartile range [IQR]: 12.5–58.5). Median ALP was 258.5 U/l, bilirubin was 1.2 mg/dl, GGT was 126.0 U/l, CRP was 5.3 mg/l and leukocyte count was 6.78/nl. For 150 of the 210 patients complete FUT2/3 genotype was available and they could be assigned to one of the previously defined, genotype-dependent CA 19-9 biosynthesis groups with low (A; n=14), intermediate Backgrounds/Aims : Autoimmune reaction towards mitochondrial antigens, such as pyruvate dehydrogenase complex E2 component (PDC-E2) is a characteristic in primary biliary cirrhosis (PBC). However, the significance of autoimmune reaction including antimitochondrial antibodies (AMAs) in the pathogenesis of bile duct lesion in PBC has not been fully clarified, so far. When we have reported the deregulated autophagy of mitochondria in biliary epithelial lesions in PBC, we noticed a unique accumulation of inflammatory cells with coarse granular expression of mitochondrial proteins (Mit-Ps) around bile ducts. In this study, we examined the extent and phenotype of inflammatory cells with coarse granular expression of Mit-Ps and its association with biliary epithelial lesions in PBC. Methods : We examined the expression of PDC-E2 and cytochrome c oxidase, subunit I (CCO) in inflammatory cells in livers taken from patients with PBC (n=35) and control diseased and normal livers (n=64), including primary sclerosing cholangitis (PSC). Mit-Ps expressing inflammatory cells were characterized by double immunofluorescence for Mit-Ps with CD3, CD4, CD8, CD20, CD38, CD56, CD68, CD79a, CD138 or myeloperoxidase (MPO). We also examined the co-localization of PDC-E2 with microtubule-associated proteins-light chain 3 β (LC3), an autophagy marker, or p62/sequestosome-1 (p62), a deregulated autophagy marker, in inflammatory cells by double immunofluorescence. Results : Infiltration of Mit-Ps expressing inflammatory cells was observed in portal tracts and around and/or in the intraepithelial layer in the damaged small bile ducts in PBC. The extent of infiltration in portal tracts was significantly higher in PBC, PSC and early stage of chronic viral hepatitis (CVH) than normal livers (p<0.01). The extent of infiltration around bile ducts and/or intraepithelial layer was significantly higher in early stage of PBC than other diseases (p<0.01). There were 2 types of Mit-Ps expressing inflammatory cells; 1) CD68 and/or MPO-positive macrophages or epithe-lioid cells and 2) CD79a, CD38 and/or CD138-positive plasma cells. LC3 and p62 were detected in inflammatory cells with expression of PDC-E2 and a co-localization of LC3 and PDC-E2 suggesting autophagy of mitochondria was seen in macrophages and plasma cells in PBC. Conclusion : Infiltration of Mit-Ps expressing macrophages and plasma cells was frequently seen around